Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Nutrien Ltd — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Nutrien Ltd trades at $69.87 (market cap $33.13B). The key difference: GE HealthCare Technologies Inc. Common Stock and Nutrien Ltd are close in size by market cap, and Nutrien Ltd pays the higher dividend (3.16%). Which is the better fit depends on your goals.
| GEHC | NTR | |
|---|---|---|
Market Cap | $31.07B | $33.13B |
Volume | 3,443,020 | 2,165,412 |
Sector | Health | Basic Materials |
52-Week High | $88.16 | $83.94 |
52-Week Low | $59.48 | $53.64 |
Enterprise Value | $39.53B | $44.94B |
Dividend Yield | 0.23% | 3.16% |
Typical Hold Time | — | 60 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
NTR trades at $69.87, up 2.75% today, with mixed technical signals showing bearish momentum but oversold conditions on some indicators. The company demonstrates solid fundamentals with $26.89B revenue, 8.44% net margin, and attractive valuation ratios including P/E of 14.11. Recent earnings show volatility with Q2 2026 missing estimates but Q1 beating expectations. Analyst sentiment remains positive with 60.61% buy ratings and $77.29 consensus target.
NTR presents a compelling value opportunity with reasonable valuations and strong cash flow generation, though facing headwinds from fertilizer industry challenges and competitive pressures. The stock's current discount to analyst targets suggests potential upside, but investors should monitor execution on cost discipline and volume recovery amid fluctuating commodity prices and geopolitical factors affecting fertilizer markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
